Actively Recruiting
Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
Led by Fondazione Policlinico Universitario Campus Bio-Medico · Updated on 2025-06-15
300
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
CONDITIONS
Official Title
Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients suffering from stage IV breast cancer
- Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)
- Candidates for radiation treatment (both palliative and curative)
You will not qualify if you...
- Previous radiation treatment on the same site
- Absolute contraindications to radiotherapy
- Systemic treatment administered as part of a clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Radiation Oncology Department Fondazione Policlinico Campus BioMedico
Rome, Italy, Italy, 00128
Actively Recruiting
Research Team
E
Edy Ippolito, Prof
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here